Charles River Laboratories International
Market Cap
US$7.0b
Last Updated
2019/12/07 23:33 UTC
Data Sources
Company Financials +
Executive Summary
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Solid track record with reasonable growth potential.
Similar Companies
Share Price & News
How has Charles River Laboratories International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRL has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.7%
CRL
1.4%
US Life Sciences
-0.3%
US Market
1 Year Return
13.5%
CRL
24.0%
US Life Sciences
18.6%
US Market
Return vs Industry: CRL underperformed the US Life Sciences industry which returned 24% over the past year.
Return vs Market: CRL underperformed the US Market which returned 18.6% over the past year.
Shareholder returns
| CRL | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.7% | 1.4% | -0.3% |
| 30 Day | 14.8% | 9.8% | 2.2% |
| 90 Day | 8.6% | 8.6% | 5.6% |
| 1 Year | 13.5%13.5% | 24.2%24.0% | 21.1%18.6% |
| 3 Year | 97.2%97.2% | 105.2%103.4% | 45.6%36.2% |
| 5 Year | 133.4%133.4% | 136.6%133.4% | 71.1%52.2% |
Price Volatility Vs. Market
How volatile is Charles River Laboratories International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Here's Why I Think Charles River Laboratories International (NYSE:CRL) Is An Interesting Stock2 weeks ago | Simply Wall St
What Charles River Laboratories International, Inc.'s (NYSE:CRL) ROE Can Tell UsValuation
Is Charles River Laboratories International undervalued compared to its fair value and its price relative to the market?
6.9%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CRL ($146.23) is trading below our estimate of fair value ($157.06)
Significantly Below Fair Value: CRL is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CRL is good value based on its PE Ratio (30.6x) compared to the Life Sciences industry average (35.7x).
PE vs Market: CRL is poor value based on its PE Ratio (30.6x) compared to the US market (18.5x).
Price to Earnings Growth Ratio
PEG Ratio: CRL is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: CRL is good value based on its PB Ratio (4.7x) compared to the US Life Sciences industry average (5.3x).
Next Steps
Future Growth
How is Charles River Laboratories International forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
16.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRL's forecast earnings growth (16.9% per year) is above the savings rate (1.7%).
Earnings vs Market: CRL's earnings (16.9% per year) are forecast to grow faster than the US market (14.2% per year).
High Growth Earnings: CRL's earnings are forecast to grow, but not significantly.
Revenue vs Market: CRL's revenue (7.7% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: CRL's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRL's Return on Equity is forecast to be high in 3 years time (22.6%)
Next Steps
Past Performance
How has Charles River Laboratories International performed over the past 5 years?
10.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRL has high quality earnings.
Growing Profit Margin: CRL's current net profit margins (9.1%) are higher than last year (6.3%).
Past Earnings Growth Analysis
Earnings Trend: CRL's earnings have grown by 10.1% per year over the past 5 years.
Accelerating Growth: CRL's earnings growth over the past year (71%) exceeds its 5-year average (10.1% per year).
Earnings vs Industry: CRL earnings growth over the past year (71%) exceeded the Life Sciences industry 34.6%.
Return on Equity
High ROE: CRL's Return on Equity (14.9%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Charles River Laboratories International's financial position?
Financial Position Analysis
Short Term Liabilities: CRL's short term assets ($972.4M) exceed its short term liabilities ($681.6M).
Long Term Liabilities: CRL's short term assets ($972.4M) do not cover its long term liabilities ($2.3B).
Debt to Equity History and Analysis
Debt Level: CRL's debt to equity ratio (120.6%) is considered high.
Reducing Debt: CRL's debt to equity ratio has increased from 110.1% to 120.6% over the past 5 years.
Debt Coverage: CRL's debt is well covered by operating cash flow (23.3%).
Interest Coverage: CRL's interest payments on its debt are well covered by EBIT (7x coverage).
Balance Sheet
Inventory Level: CRL has a high level of physical assets or inventory.
Debt Coverage by Assets: CRL's debt is not covered by short term assets (assets are 0.5x debt).
Next Steps
Dividend
What is Charles River Laboratories International's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CRL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CRL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Charles River Laboratories International's salary, the management and board of directors tenure and is there insider trading?
4.5yrs
Average management tenure
CEO
James Foster (68yo)
27.9yrs
Tenure
US$14,450,802
Compensation
Mr. James C. Foster, J.D., has been the Chairman of the Board of Charles River Laboratories, Inc. (“CRL”) since 2000 and has been its Chief Executive Officer since 1992. Mr. Foster has been the President o ...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD14.45M) is above average for companies of similar size in the US market ($USD6.81M).
Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.5yrs
Average Tenure
55yo
Average Age
Experienced Management: CRL's management team is considered experienced (4.5 years average tenure).
Board Age and Tenure
11.2yrs
Average Tenure
68yo
Average Age
Experienced Board: CRL's board of directors are seasoned and experienced ( 11.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer & Executive VP |
| Shares | 4,000 |
| Max Price | US$126.19 |
| Entity | Individual |
| Shares | 1,370 |
| Max Price | US$138.37 |
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer & Executive VP |
| Shares | 4,500 |
| Max Price | US$141.38 |
| Entity | Individual |
| Role | Chief Executive Officer Chairman |
| Shares | 200 |
| Max Price | US$129.43 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
David Johst (57yo)
Executive VP of Human Resources
- Tenure: 23.9yrs
- Compensation: US$5.27m
James Foster (68yo)
Chairman
- Tenure: 27.9yrs
- Compensation: US$14.45m
Amy Cianciaruso
Corporate Vice President of Public Relations & Corporate Communications
- Tenure: 0yrs
William Barbo (58yo)
Chief Commercial Officer & Executive VP
- Tenure: 3.2yrs
- Compensation: US$2.58m
Michael Knell (42yo)
Corporate Senior VP & Chief Accounting Officer
- Tenure: 2.7yrs
David Smith (53yo)
Corporate Executive VP & CFO
- Tenure: 4.3yrs
- Compensation: US$3.24m
Birgit Girshick (49yo)
EVP of Discovery & Safety Assessment
- Tenure: 6.2yrs
- Compensation: US$2.52m
Shanna Cotti-Osmanski
Chief Information Officer & Corporate Senior VP of Information Technology
- Tenure: 4.6yrs
Barbara Patterson
Senior Vice President of Regulatory Affairs & Compliance
- Tenure: 3.9yrs
Todd Spencer
Corporate Vice President of Investor Relations
- Tenure: 0yrs
Board Members
Stephen Chubb (75yo)
Independent Director
- Tenure: 25.9yrs
- Compensation: US$280.05k
C. Reese (74yo)
Independent Director
- Tenure: 12yrs
- Compensation: US$290.05k
Richard Wallman (68yo)
Independent Director
- Tenure: 8.9yrs
- Compensation: US$285.05k
James Foster (68yo)
Chairman
- Tenure: 27.9yrs
- Compensation: US$14.45m
George Milne (75yo)
Lead Director
- Tenure: 0yrs
- Compensation: US$305.05k
Jean-Paul Mangeolle (57yo)
Independent Director
- Tenure: 1.9yrs
- Compensation: US$280.05k
George Massaro (71yo)
Independent Director
- Tenure: 16.9yrs
- Compensation: US$300.05k
Bob Bertolini (58yo)
Independent Director
- Tenure: 8.9yrs
- Compensation: US$295.05k
Martin MacKay (63yo)
Independent Director
- Tenure: 2.4yrs
- Compensation: US$275.05k
Deborah Kochevar (62yo)
Independent Director
- Tenure: 11.2yrs
- Compensation: US$275.05k
Company Information
Charles River Laboratories International, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Charles River Laboratories International, Inc.
- Ticker: CRL
- Exchange: NYSE
- Founded: 1947
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.020b
- Shares outstanding: 48.84m
- Website: https://www.criver.com
Number of Employees
Location
- Charles River Laboratories International, Inc.
- 251 Ballardvale Street
- Wilmington
- Massachusetts
- 1887
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CRL | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jun 2000 |
| RV6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2000 |
Biography
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segm ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/07 23:33 |
| End of Day Share Price | 2019/12/06 00:00 |
| Earnings | 2019/09/28 |
| Annual Earnings | 2018/12/29 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.